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estimated cost and effectiveness for four treatment strategies: 1) Standard dual
therapy pegylated interferon alfa and ribavirin (PR); 2) BOCPR triple therapy; 3)
TELPR triple therapy; and 4) no treatment. RESULTS: In our model, patients re-
ceived 1) PR for 48 weeks; 2) TEL for 12 weeks with PR for 34-36 weeks; or 3) BOC for
29 weeks with PR for 34-36 weeks. Estimated treatment cost associated with PR
alone, BOCPR, and TELPR are about $8,300, $31,000 and $45,000 per average
patient, respectively. Total system-wide costs to adopt BOCPR or TELPR would
be $673 million and $971 million, respectively. Assuming continuation of the cur-
rent 21% VHA treatment rates and optimal SVR results, the long term reduction in
liver related death from treatment PR, BocPR, and TelPR are 7.9%, 13.1%, and
14.5%, respectively.CONCLUSIONS:Our model indicates upfront investments with
BOCPR, and TELPR are high, with the benefits of extending quality of life and
lower costs due to liver-related morbidity. Though model projected potential cost
under these assumptions, a clinical trial of comparative effectiveness would be
needed to evaluate both costs and benefits of DAAs in veterans.
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OBJECTIVES: In Brazil, switching to a protease inhibitor (PI) based ARV regimen is
recommended as second line therapy for experienced patients failing non-nucle-
oside reverse transcriptase inhibitors. The BMS-045 study compared ATVRTV
and LPV/r regimens in ARV-experienced patients. Similar viral load (VL) suppres-
sion rates 400 copies were reported, but LPV/r provided greater suppression rate
50 copies. Total cholesterol (TC) levels improved to guideline levels in 23% of
ATVRTV patients and became elevated in 7% of LPV/r patients at 48 weeks. The
long term clinical and cost impact of this difference is not yet clear. The objective of
this study was to examine the long term HRQL and economic implications in Brazil
for LPV/r versus ATVRTV treatment of ARV-experienced patients. METHODS: A
previously published HIV Markov model was adapted. Baseline assumptions: TC
profile and CD4 cell distribution matching the BMS-045 population. HRQL and sur-
vival outcomes were measured in quality adjusted life years (QALYs). Costs in
Brazilian Reale were indexed to 2011. ARV costs and HIV treatment patterns were
based on Brazilian references. Lifetime costs/outcomes were discounted at 3% per
annum. A national health services perspective was adopted. RESULTS:VL suppres-
sion differences favored LPV/r, driving a net improvement in survival (0.31 QALYs,
106 days). Five and 10 year cost savings (BRL1,816, BRL1,496 per patient) were pro-
jected for LPV/r. Lifetime costs were slightly higher for LPV/r due to improved
survival. An incremental cost effectiveness ratio (ICER) of BRL2319 per QALY gained
was estimated for the LPV/r regimen, which is highly acceptable by Brazilian
threshold . CONCLUSIONS: Compared to ATVRTV, an LPV/r based regimen is cost
saving through the first 10 years of survival and is a cost effective use of public
resources for ARV-experienced Brazilian patients. LPV/r implementation is sup-
ported by its improved viral suppression, short/long term cost savings and favor-
able ICER.
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OBJECTIVES: Research data on antibiotic usage pattern and cost comparison are
scant in our country. Therefore we planned to identify oral antibiotic (OA) con-
sumption and cost comparison for 2010 in tertiary care hospital in Sri Lanka.
METHODS: Aggregate data for 2010 was collected from records of pharmacy and
unit price was obtained from medical supplies division. Initial and final stocks of
the OA, quantity received, quantities issued, quantity consumed and hospital data
from VEN analysis were obtained. We identified the top ten for total cost (TTTC)
and top ten for consumption (TTCS) OA. RESULTS: Ninethy-three percent of total
cost for TTTC was utilized for the top seven highly consumed OA with low unit
price. Seven percent of TTTC had been utilized for the drugs which were not in
TTCS. In contrast three drugs in TTCS had not been included in TTTC but in the list
of top 20. Low quota ( 2.5%) of the TTTC had been utilized for non essential drug in
VEN which was not even in TTCS of OA. CONCLUSIONS: Ninety-three percent of
the cost has been effectively utilized highly consumed low cost OA in this hospital
for 2010. Seven percent of money in TTTC was spent for expensive OA. We suggest
the authority to reconsider the change the drug ordering pattern with minimum
cost and to suitable alternative low cost generics instead of expensive product.
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OBJECTIVES: We planned to identify the 2010 parenteral antibiotic (PA) consump-
tion pattern and its cost effectiveness in government teaching hospital using ag-
gregate data. METHODS: Aggregate data for 2010 was collected from pharmacy
records and unit prize was obtained from medical supplies division. Initial and final
stocks of the OA, quantity received, quantities issued and consumed per year were
obtained. Data for VEN analysis was collected. Data was analyzed to identify the
top ten for total cost (TTTC) and top ten for consumption (TTCS) PA according to the
total cost and the consumption separately. RESULTS: Ninety-three perecent of
TTTC was utilized for the top 7 highly consumed OA with low unit prize. Seven
percent of expenditure of TTTC was utilized for drugs which were not included in
TTCS. In contrast 3% of drugs (3 OA) in TTCS had not been included in TTTC. This
indicates that these three OAs are cost effectively used. 2.5% of the TTTC had been
used for a non essential drug in VEN which was not included even in TTCS of OA.
CONCLUSIONS: We conclude that 93% of the cost has been effectively utilized
highly consumed low cost OA in this hospital for 2010. Seven percent of the TTTC
had been spent for expensive oral antibiotics. We suggest the authority to recon-
sider the change the drug orders to maximize the cost effectiveness and prioritize
alternative low cost generics instead of expensive product orders.
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OBJECTIVES: One third of skin and soft tissue infections (SSTI) are caused by me-
thicilin-resistant staphylococcus aureus (MRSA). This study aims to compare SSTI-
MRSA treatment costs with linezolid versus branded and generic vancomycin un-
der the Brazilian private payer perspective. METHODS: A cost comparison study
was performed to compare linezolid versus generic and branded vancomycin. As
supported by clinical studies, overall treatment duration of 15 days with linezolid
and 14 days with vancomycin was considered, using PO linezolid after a minimum
4-days cycle of IV infusion while vancomycin (1g bid) was entirely IV. A decision-
tree model simulated SSTI-MRSA treatment assuming linezolid (600mg bid) IV can
be switched to PO after 4-days and patients can be discharged if PO is implemented
at physician discretion. Length of stay (LOS) and IV linezolid duration were ranged
in one-way sensitivity analysis. Only direct medical costs were included in the
analysis (hospital charges, medical visits, medical supplies and drug acquisition
costs) and unit costs were obtained from Brazilian official price lists (2010 USD
values). RESULTS: The linezolid scheme with 4-days IV (LOS4 days) and 11-days
PO resulted in overall costs per patient of 4089.58 USD, while branded and generic
vancomycin exhibited 6657.33 USD and 6970,23 USD, respectively. The incremental
cost of vancomycin-treated patients was driven by hospital daily charges, respon-
sible for over 55% of the overall vancomycin costs. One-way sensitivity analysis
revealed cost-savings for linezolid up to LOS 12 days, with overall costs per pa-
tient ranging from 4089.58 to 7428.84 USD if IV therapy was maintained throughout
the inpatient period (LOS15 days). CONCLUSIONS: Linezolid exhibited a cost-
saving profile over branded or generic vancomycin for the treatment of SSTI-MRSA
under the Brazilian public payer perspective. This economic benefit was a direct
result of potential early discharge of patients receiving PO linezolid.
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OBJECTIVES: Voriconazole (VOR) demonstrated better tolerability with a longer
treatment duration and less concomitant systemic antifungal drugs (con AF) com-
pared to itraconazole (ITR). This study assessed key cost components associated
with prophylaxis treatment of IFI after allogeneic HSCT across 4 countries (Canada,
France, Germany, and US). METHODS: A prospective open-label multicenter clini-
cal trial (IMPROVIT) for primary IFI prophylaxis after HSCT included patients12
years who were randomized to oral VOR or oral ITR from HSCT day for at least 100
and up to 180 days. Trial data on the key medical resource utilization (including
hospital days and con AF use) for the first 100 days were analyzed and valued in
2010 costs. RESULTS:A total of 224 patients were in VOR and 241 in ITR group, with
similar demographics (average age 43-year, 59% male, 92% Caucasian). VOR pa-
tients (vs. ITR) had longer study drug exposure (median: 96 vs. 68 days, p0.0001;
mean: 68 vs. 60 days, p0.0162) and were 2 times less likely (P0.0032) to use con
AF. The average per-patient hospital cost for voriconazole (vs. itraconazole) was
Can$27,674 (vs. Can$29,669), €13,277 (vs. €13,632), €15,185 (vs. €15,762), and $31,916
(vs. $33,521) in Canada, France, Germany, and the U.S., respectively. The average
per-patient cost of con AF for voriconazole (vs. itraconazole) was Can$1028 (vs.
Can$2290 p0.0061), €2208 (vs. €4678, p0.0095), €2422 (vs. €5033, p0.0177), and
$1,720 (vs. $3612, p0.0146) in the study countries respectively. Total costs varied
by country and were similar between treatment groups. The mean difference of 8
days in prophylaxis days between VOR and ITR was associated with 3.54%-4.55%
reduction (depending on the country) in inpatient cost (all p.0001) and 9.13%-
11.82% reduction in con AF cost (all p.01). CONCLUSIONS: Better tolerability of IFI
prophylaxis after HSCT was associated with cost offsets due to reduced hospital-
ization and concomitant antifungal use.
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OBJECTIVES: In Uganda, mother to child transmission (MTCT) of HIV is responsible
for approximately 25,000 infections among newborns annually and is the third
leading cause of new infections. This analysis attempts to quantify the financial
and disease burden associated with MTCT of HIV in Uganda. METHODS: Whereas
HIV-negative infants have a life expectancy at birth ranging from 52.2 years for
males and 54.3 years for females, the life expectancy of HIV-positive infants varies
from 2 years in the absence of antiretroviral therapy (ART) to about 14.2 years with
ART. Approximately 18% of eligible children in Uganda have access to ART, at an
annual treatment cost of US$328. Lifetime health-care costs of HIV-positive un-
treated infants are assumed to be US$495. The model calculates years of life lost
(YLL) as the difference in life-expectancy between HIV-positive and HIV-negative
newborns and years of life lived with disability (YLD) by applying the relevant
disability weights of 0.123 for each year lived with HIV and 0.5 for the last year of life
with AIDS. All costs and life years are discounted at 3% annually. RESULTS: The
total annual disease burden resulting from mother to child transmission of HIV is
estimated at 592,480 disability adjusted life years (DALY’s), which is defined as the
sum of YLL: 572,662 and YLD: 19,818. The discounted net present value of future
health care costs associated with mother to child transmission of HIV is estimated
at US$27.3 Million. CONCLUSIONS: Mother to child transmission of HIV is associ-
ated with a substantial mortality and morbidity burden in Uganda. The financial
burden is also worrisome in a country with annual health expenditures of US$24
per capita (circa US$ 830 Million total). Cost-effective strategies to reduce the inci-
dence of MTCT that can be scaled-up nationally are urgently needed.
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OBJECTIVES: To determine the cost of non-CF bronchiectasis patients enrolled in a
managed care plan. METHODS: Data were obtained from a large employer-based
claims database. A cohort of bronchiectasis patients (cases) with and without acute
exacerbations was identified using ICD-9 494.0 and 494.1 codes and matched (1:3)
on demographics to those without the disease (controls) from January 1, 2005-
December 31, 2009. Index event for cases were defined as the first medical claim of
bronchiectasis during the study period and controls were assigned the same index
event to whom they were matched. Cases had no medical claim for cystic fibrosis
and chronic obstructive pulmonary disorder 12 months prior (baseline) and post
index event. Medical resource use and expenditures were estimated for 12 months
before and after index event. All statistical tests were conducted using SAS 9.2.
RESULTS: The final study sample included 9,146 cases and 27,438 matched con-
trols. 64% and 50% of the sample was females and between 45-64 years of age at
index date, respectively. 37%, 29%, and 27% of the sample was enrolled in a POS,
HMO, or PPO type of health plan. Overall comorbidity burden as measured by the
Charlson comorbidity score and respiratory conditions other than bronchiectasis
were significantly (p.001) greater at baseline among cases vs. controls. The incre-
mental overall ($2,128 vs. $783) and respiratory-related ($896 vs. $100) costs were
significantly (p.001) greater among cases vs. controls. The difference was primar-
ily driven by an increase in outpatient care visits (2.21 vs. 0.43), emergency room
visits (0.31 vs. 0.08) and pharmacy scripts (3.58 vs. 0.83) in the post-index period vs.
baseline in cases vs. controls. CONCLUSIONS: The study found that overall incre-
mental economic impact of non-CF bronchiectasis to a health plan was $1345 per
patient. Further research needs to identify the impact of current treatment on the
burden of the disease.
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OBJECTIVES:To analyze the changes in the antiretroviral pharmacotherapy during
2006-2010 and its impact on cost and disease control of HIV/AIDS patients in
Bulgaria.METHODS:Micro costing approach was used based on retrospective anal-
ysis of patients’ records in major clinic for immunosuppressed patients at the
University hospital of infectious and parasitic diseases in Sofia. Information was
gathered for the way of diseases transmission, antiretroviral combinations and
their cost, CD4 count and viral load per patient per year. It was evaluated the
changes in the dosage regimes, cost of therapy and its influence on CD4 count and
viral load. RESULTS: On total 162 patients were included in the study. Nearly 40
different dosage regimes were identified and all of them are combinations of 3 or 4
medicines. During the period were introduces 3 new antiretroviral medicines
(tenofovir, emtricitabin, darunavir). The average yearly cost of pharmacotherapy
(all regimes and patients) is increasing from 155 837.64 euro to 319 571.76 euro
during 2006 - 2010 due to switch of the therapy for some of the patients to newer
medicines because of drug toxicity, resistance or other reasons. All newly regis-
tered patients are treated with the new antiretroviral products and their yearly cost
of therapy is 178251.12 euro. Introduction of the new medicines led to the increase
in total pharmacotherapy cost with 291 89.64 euro, but also to better control mea-
sured with the increase in CD4 count (500) and sustained suppression of vial load
to 20 in 45.46% of patients. CONCLUSIONS: HIV/AIDS remain costly diseases for
the Bulgarian population but new medicines led to better control on its progress
and thus could save further hospital cost.
PIN34
COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS (RSV)
VACCINATION OF DUTCH ELDERLY
Pouwels K1, Meijboom M1, Luytjes W2, Hak E1, Postma M1
1University of Groningen, Groningen, Groningen, The Netherlands, 2National Institute for Public
Health and the Environment (RIVM), Bilthoven, Utrecht, The Netherlands
OBJECTIVES: Respiratory syncytial virus (RSV) is increasingly recognized as an
important cause of morbidity, mortality and health-care resource use in the el-
derly. Therefore we determined whether there are specific levels of vaccine cost
and effectiveness for which a hypothetical RSV-vaccine for Dutch elderly could be
cost-effective.METHODS: The annual excess RSV-associated age- and risk-specific
burden was estimated using a rate-difference method. Different vaccination strat-
egies were evaluated, for various levels of vaccine effectiveness and different levels
of willingness to pay per quality-adjusted life year gained (QALY). Outcome mea-
sures included costs, QALYs, life years gained (LYGs), and the amount of money
that can be spent per vaccination, while remaining cost-effective. RESULTS: Sig-
nificant excess RSV-associated deaths, hospitalisations, GP-visits and antibiotic
prescriptions were found. The burden of RSV increased with age and was higher for
high-risk (HR) elderly than for low-risk (LR) elderly. For several scenarios vaccina-
tion of the Dutch elderly appeared to be cost-effective. Using base-case assump-
tions, the amount of money that can be spent per vaccination, while remaining
cost-effective, ranged from €26 when vaccinating all 60 elderly to €68 when vac-
cinating only 85 elderly, for a willingness to pay of €50,000 per QALY and a vaccine
effectiveness of 70%. For HR-elderly only these estimates ranged from €52 to €99.
CONCLUSIONS: Vaccination of Dutch elderly with a hypothetical RSV vaccine was
found cost-effective for several scenarios. Vaccination is more likely to be cost-
effective when vaccinating only HR elderly than when vaccinating all elderly, de-
spite a decreased life expectancy and quality of life and a decreased effectiveness
of the vaccine assumed in HR-elderly in the model. This study shows the major
burden of RSV in the Dutch elderly, potential cost-effectiveness of vaccination,
stressing the need to have an effective vaccine available shortly.
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OBJECTIVES: Cases of genital warts (GW), caused by human papillomavirus (HPV),
remains a significant problem in the UK. Costs to the National Health Service (NHS)
to manage GW have been recently estimated, but studies excluded treatment by
General Practitioners (GP) and costed resources without inclusion of full staff time
and overheads thereby underestimating the full cost impact. This study estimates
the cost of GW management taking account of all identified GW cases seeking care
and applying the full NHS cost algorithm. METHODS: The number of GW cases
obtained from the surveillance of Genitourinary Medicine (GUM) clinics by Health
Protection Agency (HPA) and estimated number of GP visits (using THIN data) for
GW were combined and projected to 2010. The number of visits and therapy re-
quired for GW management were estimated by GUM experts for standard and
hard-to-treat patients. NHS payment by results (PbR) tariffs were applied to esti-
mate GUM resource costs and GP visit and therapy costs estimated from PSSRU and
BNF data. RESULTS: Extrapolating to 2010, there were 173,077 GUM clinic (33.5%
recurrent, 11% persistent) and 16,882 primary care GW episodes excluding referrals
to GUM. Approximately 2% of GUM cases were estimated to be hard-to-treat, re-
quiring additional visits and resources. Resulting NHS costs were £52.4 million
(average £273/female; £278/male patient). The proportion hard-to-treat was the
most sensitive variable for overall national costs.CONCLUSIONS:The £52.4 million
includes the full per patient costs for GUM clinics and costs for GP visits not previ-
ously estimated. This is higher than previous estimates and reflective of real NHS
costs. The full cost of GW management is important to understand and quantify
when considering the potential value of introducing a quadrivalent HPV vaccina-
tion in the UK. This is relevant from both a public health and health economic
perspective.
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OBJECTIVES: Surgical site infections (SSIs) are a significant burden to healthcare
systems negatively affecting Medicare reimbursement, quality and hospital repu-
tation. This study quantifies the economic impact of SSIs across multiple institu-
tions in the United States (US) using more up-to-date real-world data METHODS:
The economic impact of SSIs was evaluated in following surgeries (colon, hernia,
CABG, shunt, abdominal and vaginal hysterectomy, c-section, hip and knee pros-
thesis, spinal fusion, abdominoplasty and breast surgery). The data source was the
Premier Perspective™ Comparative Database, a national administrative discharge
database (2007-2010) from about 500 hospitals throughout the US. The SSIs were
identified by a combination of post-operative infection diagnosis codes, or postop-
erative prescription of selected antimicrobial drugs with treatment duration 5
days. The outcomes included rates of SSI by surgical category, the impact of SSI on
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